TrivarX to acquire brain imaging tech from Nucleics
SYDNEY: TrivarX Ltd (ASX: TRI) said on Thursday it will acquire the intellectual property for Stabl-Im™, a novel brain cancer imaging technology, from Australian biotech firm Nucleics Pty Ltd, in a deal aimed at expanding its diagnostics portfolio into neuro-oncology. The Perth and Minneapolis-based company has entered a binding option agreement to acquire 100% of…